studies

mHCC - 1st line (L1), immune chekpoint inhibitors vs. lenvatinib, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsLEAP 002, 2023 0.84 [0.71; 1.00] 0.84[0.71; 1.00]LEAP 002, 202310%794NAnot evaluable progression or deaths (PFS)detailed resultsLEAP 002, 2023 0.87 [0.74; 1.03] 0.87[0.74; 1.03]LEAP 002, 202310%794NAnot evaluable AE (any grade)detailed resultsLEAP 002, 2023 1.22 [0.59; 2.52] 1.22[0.59; 2.52]LEAP 002, 202310%790NAnot evaluable AE (grade 3-4)detailed resultsLEAP 002, 2023 1.22 [0.92; 1.62] 1.22[0.92; 1.62]LEAP 002, 202310%790NAnot evaluable AE leading to death (grade 5)detailed resultsLEAP 002, 2023 1.34 [0.30; 6.01] 1.34[0.30; 6.01]LEAP 002, 202310%790NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsLEAP 002, 2023 1.84 [1.22; 2.78] 1.84[1.22; 2.78]LEAP 002, 202310%790NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-10-02 01:00 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 131 - treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743